TITLE

Combination study of Invirase and Norvir starting

PUB. DATE
June 1996
SOURCE
AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Announces the clinical trial to be conducted by Hoffman-La Roche Inc. with Abbott Laboratories on the protease inhibitors Invirase in combination with Norvir and their effectiveness in the treatment of HIV/AIDS. Distinct mutation profile of Invirase.
ACCESSION #
9709124515

 

Related Articles

  • saquinavir:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p195 

    An encyclopedia entry for saquinavir is presented. Saquinavir is the first protease inhibitor approved by the U.S. Food and Drug Administration. The drug was approved more quickly than any other new HIV drug at that time. Saquinavir is manufactured by Roche Laboratories, with the trade name...

  • New & improved.  // Pharmaceutical Executive;Feb98, Vol. 18 Issue 2, p108 

    Reports that the US Food and Drug Administration has granted marketing clearance for Hoffman-La Roche's Fortovase (saquinavir), a soft gelatin formulation of the first available protease inhibitor. Indication of the drug.

  • Roche files saquinavir NDA.  // Drug Topics;9/18/95, Vol. 139 Issue 18, p8 

    Reports on Hoffman-LaRoche's submission of a new drug application for Invirase or saquinavir, a protease inhibitor used in the treatment of AIDS.

  • Protease inhibitors raising quality-of-life issues for HIV patients. Silversides, Ann // CMAJ: Canadian Medical Association Journal;3/23/99, Vol. 160 Issue 6, p894 

    Discusses the rising concern from AIDS activists and physicians who treat HIV/AIDS patients regarding body shape and metabolic changes associated with protease inhibitors. Efforts by Dr. David Cooper to develop a consensus case definition of the condition, which is referred to as lipodystrophy;...

  • NDA for ritonavir.  // Drug Topics;2/5/96, Vol. 140 Issue 3, p28 

    Reports on the submission of a New Drug Application by Abbott Laboratories for the ritonavir protease inhibitor.

  • Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System. Mahdi, Mohamed; Szojka, Zsófia; Mótyán, János András; Tőzsér, József // Viruses (1999-4915);2015, Vol. 7 Issue 12, p6152 

    Retroviral protease inhibitors (PIs) are fundamental pillars in the treatment of HIV infection and acquired immunodeficiency syndrome (AIDS). Currently used PIs are designed against HIV-1, and their effect on HIV-2 is understudied. Using a modular HIV-2 protease cassette system, inhibition...

  • Combination shows reduction in viral levels.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p184 

    Reports on the effectiveness of the protease inhibitor Crixivan in triple combination with two other anti-retrovirals on the reduction of HIV levels in the bloodstream. Effect of the combination on the immune system.

  • Phase II/III trials of Viracept start.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187 

    Focuses on the initiation of phase II and III of the clinical trials held of the effectiveness of the protease inhibitor Viracept in the treatment of HIV infections. Two doses to be evaluated in the trial; Reported adverse effects of the drug.

  • Ritonavir increases lymphocyte subsets.  // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p307 

    Reports on the benefits from protease inhibitor ritonavir (Norvir) to HIV patients. Changes noted among the respondents' cell counts; Viral load reductions; Increases in CD4 and CD8 lymphocytes; Increase in `in vitro' cell responses to antigens.

Share

Read the Article

Other Topics